Business
Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium
Detailed results from the KARISMA-Endoxifen trial demonstrating (Z)-endoxifen’s ability to significantly reduce mammographic breast density to be featured at
About this update from Atossa Therapeutics, Inc.
[{"type":"text","content":"Detailed results from the KARISMA-Endoxifen trial demonstrating (Z)-endoxifen’s ability to significantly reduce mammographic breast density to be featured at conference\nSEATTLE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that five abstracts featuring data on (Z)-endoxifen have been accepted for presentation at the San Antonio Breast Cancer Symposium (SABCS), taking place December 10-13, 2024, in San Antonio, Texas. The presentations will showcase significant findings from various studies evaluating the use of (Z)-endoxifen in breast cancer prevention and treatment, including phase 2 trials and innovative combination therapy research. “We are excited to present a comprehensive body of research on (Z)-endoxifen at SABCS 2024,” said Dr. Steven Quay, President and Chief Executive Officer of Atossa Therapeutics. “These presentations highlight our commitment to advancing breast cancer treatment and prevention, showcasing the potential of (Z)-endoxifen to bring meaningful treatment options to patients with breast cancer.” Abstract Highlights and Presentation Details:Poster Spotlight Session 16Title: PS16-05 Primary Breast Cancer Prevention Using Oral Endoxifen Description: Evaluates the effectiveness of low-dose (Z)-endoxifen in reducing mammographic breast density, a significant risk factor for breast cancer.Poster Details: Per Hall, Karolinska Institutet, 5:30-6:00 pm, Thursday, December 12 Title: P2-03-07 Neoadjuvant Z-endoxifen for Premenopausal Estrogen Receptor (ER)+, Human Epidermal Receptor (HER2)- Breast Cancer (BC): Evaluation of Quality of Life (QOL) measures in the EVANGELINE Study: Description: Reports on quality of life outcomes, menopausal symptoms, and patient-reported experiences of (Z)-endoxifen treatment in premenopausal women with ER+/HER2- breast cancer.Presentation Details: Sarah Premji, 5:30-7:00 pm, December 11, 2024 Title: P1-11-04 Neoadjuvant Z-endoxifen for Premenopausal Estrogen Receptor (ER)+, Human Epidermal Growth Factor Receptor (HER2)- Breast Cancer (BC): Evaluation of the Pharmacokinetic (PK) Run-in for the EVANGELINE Study: Description: Details the PK profile and opt...